Literature DB >> 19852062

Coding microsatellite instability analysis in microsatellite unstable small intestinal adenocarcinomas identifies MARCKS as a common target of inactivation.

Sara Michel1, Matthias Kloor, Sandhya Singh, Georg Gdynia, Wilfried Roth, Magnus von Knebel Doeberitz, Peter Schirmacher, Hendrik Bläker.   

Abstract

Approximately 15% of small intestinal adenocarcinomas show inactivation of DNA-mismatch repair (MMR) and display high-level microsatellite instability (MSI-H). MSI-H tumors progress as a result of mutations affecting coding microsatellites (coding microsatellite instability, cMSI) that may result in a functional inactivation of the encoded proteins and provide a selective growth advantage for the affected cell. To investigate the cMSI selection in small intestinal carcinogenesis 56 adenocarcinomas were tested for MSI. Eleven MSI-H carcinomas (19.6%) were identified and subjected to cMSI analysis in 24 potentially tumor relevant genes. Mutation frequencies were similar to those observed in colorectal cancer (CRC). Beside high frequencies of cMSI in TGFbetaR2, ACVR2, and AIM2 we detected MARCKS mutations in 10 out of 11 (91%) tumors with a 30% share of biallelic mutations. Since little is known about MARCKS expression in the intestine, we analyzed MARCKS protein expression in 31 carcinomas. In non-neoplastic mucosa, MARCKS was found to be expressed with a concentration gradient along the crypt-villus axis. In line with cMSI induced functional inactivation of MARCKS, 8 out of 11 MSI-H adenocarcinomas showed regional or complete loss of the protein. In microsatellite stable (MSS) small bowel adenocarcinoma, loss of MARCKS expression was seen in 2 out of 20 tumors (10%). In conclusion, we herein present a cMSI profile of MSI-H small intestinal adenocarcinomas identifying MARCKS as a frequent target of mutation. Loss of MARCKS protein expression suggests a significant role of MARCKS inactivation in the pathogenesis of small intestinal adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19852062     DOI: 10.1002/mc.20587

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  12 in total

1.  A peptide that inhibits function of Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) reduces lung cancer metastasis.

Authors:  C-H Chen; P Thai; K Yoneda; K B Adler; P-C Yang; R Wu
Journal:  Oncogene       Date:  2013-08-19       Impact factor: 9.867

2.  Mucinous phenotype and CD10 expression of primary adenocarcinoma of the small intestine.

Authors:  Reiko Kumagai; Kenichi Kohashi; Shunsuke Takahashi; Hidetaka Yamamoto; Minako Hirahashi; Kenichi Taguchi; Kenichi Nishiyama; Yoshinao Oda
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

3.  MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma.

Authors:  John S Jarboe; Joshua C Anderson; Christine W Duarte; Tapan Mehta; Somaira Nowsheen; Patricia H Hicks; Alexander C Whitley; Timothy D Rohrbach; Raymond O McCubrey; Sherard Chiu; Tamara M Burleson; James A Bonner; G Yancey Gillespie; Eddy S Yang; Christopher D Willey
Journal:  Clin Cancer Res       Date:  2012-05-22       Impact factor: 12.531

Review 4.  Clinical practice guidelines for duodenal cancer 2021.

Authors:  Kenji Nakagawa; Masayuki Sho; Mitsuhiro Fujishiro; Naomi Kakushima; Takahiro Horimatsu; Ken-Ichi Okada; Mikitaka Iguchi; Toshio Uraoka; Motohiko Kato; Yorimasa Yamamoto; Toru Aoyama; Takahiro Akahori; Hidetoshi Eguchi; Shingo Kanaji; Kengo Kanetaka; Shinji Kuroda; Yuichi Nagakawa; Souya Nunobe; Ryota Higuchi; Tsutomu Fujii; Hiroharu Yamashita; Suguru Yamada; Yukiya Narita; Yoshitaka Honma; Kei Muro; Tetsuo Ushiku; Yasuo Ejima; Hiroki Yamaue; Yasuhiro Kodera
Journal:  J Gastroenterol       Date:  2022-10-19       Impact factor: 6.772

5.  MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion.

Authors:  Ilan Elson-Schwab; Anna Lorentzen; Christopher J Marshall
Journal:  PLoS One       Date:  2010-10-04       Impact factor: 3.240

Review 6.  MARCKS and Lung Disease.

Authors:  Mary K Sheats; Qi Yin; Shijing Fang; Joungjoa Park; Anne L Crews; Indu Parikh; Brian Dickson; Kenneth B Adler
Journal:  Am J Respir Cell Mol Biol       Date:  2019-01       Impact factor: 6.914

7.  MARCKS regulates tonic and chronic active B cell receptor signaling.

Authors:  Chenguang Xu; Yan Fang; Zhiyong Yang; Yukai Jing; Yonghui Zhang; Chaohong Liu; Wanli Liu
Journal:  Leukemia       Date:  2018-09-12       Impact factor: 11.528

8.  Absent in Melanoma 2 (AIM2) is an important mediator of interferon-dependent and -independent HLA-DRA and HLA-DRB gene expression in colorectal cancers.

Authors:  J Lee; L Li; N Gretz; J Gebert; S Dihlmann
Journal:  Oncogene       Date:  2011-08-01       Impact factor: 9.867

9.  Lynch syndrome-related small intestinal adenocarcinomas.

Authors:  Sun-Young Jun; Eui-Jin Lee; Mi-Ju Kim; Sung Min Chun; Young Kyung Bae; Soon Uk Hong; Jene Choi; Joon Mee Kim; Kee-Taek Jang; Jung Yeon Kim; Gwang Il Kim; Soo Jin Jung; Ghilsuk Yoon; Seung-Mo Hong
Journal:  Oncotarget       Date:  2017-03-28

10.  MARCKS promotes invasion and is associated with biochemical recurrence in prostate cancer.

Authors:  Emma Dorris; Amanda O'Neill; Karen Hanrahan; Ann Treacy; R William Watson
Journal:  Oncotarget       Date:  2017-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.